349 related articles for article (PubMed ID: 1713814)
1. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
3. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
4. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
[TBL] [Abstract][Full Text] [Related]
5. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
7. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
Kawase I; Shirasaka T; Ikeda T; Hara H; Tanio Y; Watanabe M; Saito S; Masuno T; Kishimoto S; Yamamura Y
Jpn J Cancer Res; 1989 Nov; 80(11):1098-105. PubMed ID: 2481664
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
10. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
Ettinghausen SE; Puri RK; Rosenberg SA
J Natl Cancer Inst; 1988 Apr; 80(3):177-88. PubMed ID: 3258039
[TBL] [Abstract][Full Text] [Related]
11. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
[TBL] [Abstract][Full Text] [Related]
12. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
Swisher SG; Economou JS; Holmes EC; Golub SH
Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
[TBL] [Abstract][Full Text] [Related]
14. Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.
Tunru IS; Suzuki H; Kobayashi M
Experientia; 1993 Jan; 49(1):76-9. PubMed ID: 7679079
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
16. Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Kim B; Warnaka P
J Surg Res; 1991 Jan; 50(1):40-6. PubMed ID: 1987429
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
[TBL] [Abstract][Full Text] [Related]
18. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
19. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
Lefor AT; Rosenberg SA
J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
[TBL] [Abstract][Full Text] [Related]
20. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1990 Sep; 50(17):5543-50. PubMed ID: 2386960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]